Screener
LeMaitre Vascular LMAT Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by LeMaitre Vascular in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: LeMaitre Vascular’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333762
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Stock option awards | $813 | $910 | $1,677 | $1,810 |
| Restricted stock units | 688 | 634 | 1,357 | 1,320 |
| Performance-based restricted stock units | 434 | 400 | 993 | 860 |
| Total stock-based compensation | $1,935 | $1,944 | $4,027 | $3,990 |
Item 1. Financial Statements
FAQ
- What is LeMaitre Vascular's stock-based comp?
- LeMaitre Vascular (LMAT) reported stock-based comp of $1.94M in Q2 2026.
- How has LeMaitre Vascular's stock-based comp changed year-over-year?
- LeMaitre Vascular's stock-based comp decreased by 0.5% year-over-year, from $1.94M to $1.94M.
- What is the long-term trend for LeMaitre Vascular's stock-based comp?
- Over 4 years (2021 to 2025), LeMaitre Vascular's stock-based comp has grown at a 22.5% compound annual growth rate (CAGR), from $3.48M to $7.83M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about LeMaitre Vascular's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude